RecruitingNCT07408219
A Real-world Study of Remibrutinib in Chronic Spontaneous Urticaria Patients
RELIEF: Remibrutinib in Chronic Spontaneous Urticaria: Early Real World Effectiveness and Satisfaction Survey
Sponsor
Novartis Pharmaceuticals
Enrollment
350 participants
Start Date
Jan 17, 2026
Study Type
OBSERVATIONAL
Conditions
Summary
This is a United States (US) based, prospective, non-interventional, provider-referral study to evaluate the real-world effectiveness and patient-centered outcomes of remibrutinib in chronic spontaneous urticaria (CSU) patients using validated patient reported outcome (PRO) tools.
Eligibility
Min Age: 18 YearsMax Age: 100 Years
Inclusion Criteria4
- Healthcare provider (HCP) participants eligible to refer patients for inclusion in this study must meet all the following criteria:
- Have an active medical license and be board certified/board eligible allergist or dermatologist in the US. Nurse practitioners and physician assistant practicing in allergy and dermatology are eligible.
- Manage CSU patients within their practice.
- Enrolled in the research network or are referred HCPs who agree to participate.
Exclusion Criteria13
- Patients eligible for inclusion in this study must meet all of the following criteria:
- ≥ 18 years of age.
- Diagnosed with CSU by an HCP.
- Have received a prescription for remibrutinib or dupilumab and are expected to initiate treatment.
- Have access to an electronic device with internet capabilities.
- Able to read and understand English.
- Willing and able to provide consent for study participation.
- Patients will be excluded if they meet any of the following criteria:
- Unable to procure remibrutinib or dupilumab (through samples, commercially or patient assistance program).
- Exposure to oral corticosteroid treatment in 14 days prior to consent.
- Exposure to oral corticosteroid treatment in 14 days prior to initiating treatment with remibrutinib or dupilumab.
- Prior participation in a remibrutinib or dupilumab clinical trial.
- Cognitive impairment that impacts the patient's ability to participate.
Interested in this trial?
Get notified about updates and connect with the research team.
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT07408219
Related Trials
24 Weeks Double-blind Randomized Placebo-controlled Trial to Evaluate Efficacy, PK, Safety of LOU064 in Adolescents (12 - <18) With CSU and Inadequate Response to H1-antihistamine Followed by Optional 3 Years Open-label Extension and an Optional 3 Years Safety Long-term Treatment-free Follow-up
NCT0567745165 locations
Long-term Efficacy and Safety Extension (LTE) Study of Barzolvolimab in Participants With Chronic Spontaneous Urticaria
NCT0725639220 locations
A Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single and Multiple Doses of EDP-978 in Healthy Adults
NCT075409101 location
Remibrutinib in Real-world Clinical Practice
NCT073583641 location
A Study to Describe the Real-world Effectiveness, Safety and Patterns of Use of Dupilumab in Patients With Chronic Spontaneous Urticaria
NCT073161141 location